公开(公告)号：US20210015878A1

公开(公告)日：2021-01-21

申请号：US17042822

申请日：2019-03-28

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan T. ORONSKY ,  Tony R. REID

IPC: A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

公开(公告)号：US20200375982A1

公开(公告)日：2020-12-03

申请号：US16712148

申请日：2019-12-12

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski

IPC: A61K31/495 ,  A61K31/397 ,  A61K9/00 ,  A61K31/4745

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

公开(公告)号：US20200345689A1

公开(公告)日：2020-11-05

申请号：US16960443

申请日：2019-01-08

Applicant: EpicentRx, Inc.

Inventor： Bryan T. ORONSKY ,  Amold ORONSKY

IPC: A61K31/397 ,  A61K9/00 ,  A61K31/616 ,  A61K45/06 ,  A61K31/196 ,  A61K31/517 ,  A61K33/00 ,  A61N5/10 ,  A61N5/06 ,  A61P39/00

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US20200022952A1

公开(公告)日：2020-01-23

申请号：US16284035

申请日：2019-02-25

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski ,  Susan Knox ,  William Fitch ,  Frans A. Kuypers ,  Marcel Fens ,  Sandra Larkin ,  Pedro Cabrales ,  Chad Brouse

IPC: A61K31/397 ,  A61K33/00 ,  A61K45/06 ,  A01N1/02 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/17 ,  A61N5/10 ,  A61K31/22 ,  A61K31/12 ,  A61K31/255 ,  A61K31/445 ,  A61K31/215 ,  A61K31/16 ,  A61K31/198 ,  A61K31/40 ,  A61K47/64

Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

公开(公告)号：US09987270B1

公开(公告)日：2018-06-05

申请号：US15337378

申请日：2016-10-28

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski

IPC: A61K31/495 ,  A61K31/397 ,  A61K31/4745 ,  A61N5/10 ,  A61K9/00

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/397 ,  A61K31/4745 ,  A61N5/10

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

公开(公告)号：US20180134766A1

公开(公告)日：2018-05-17

申请号：US15717199

申请日：2017-09-27

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  C07K16/00 ,  A61K35/768 ,  C12N7/00 ,  A61P35/00

CPC classification number: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10332 ,  C12N2710/10333 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20160081981A1

公开(公告)日：2016-03-24

申请号：US14849783

申请日：2015-09-10

Applicant: EpicentRx, Inc.

Inventor： JAN SCICINSKI ,  Bryan T. Oronsky

IPC: A61K31/397 ,  A61N5/10 ,  A61K38/05

CPC classification number: A61K31/397 ,  A61K31/19 ,  A61K31/198 ,  A61K31/215 ,  A61K31/337 ,  A61K38/05 ,  A61K45/06 ,  A61N5/10 ,  C07D205/04

Abstract: The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof.

Abstract translation: 本发明提供有机硫醚化合物，含有这些化合物的组合物，分离的有机硫醚化合物和使用这些化合物和组合物治疗患者癌症的方法。 本文所述的示例性有机亚硫醚化合物包括2-（3,3-二硝基吖丁啶-1-基）-2-氧代乙基硫醚及其变体。

公开(公告)号：US20150246020A1

公开(公告)日：2015-09-03

申请号：US14584177

申请日：2014-12-29

Applicant: EPICENTRX, INC. ,  ALLIANT TECHSYSTEMS INC.

Inventor： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: A61K31/397

CPC classification number: A61K31/397 ,  A61K9/0019 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.